Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. (CUE) on July 1, 2025, regarding events occurring on June 30, 2025. The filing discloses the entry into a material definitive agreement concerning the Company's lease obligations.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial data disclosed relates to the amended lease agreement:
- Previous Monthly Rental Rate: $235,883.98
- New Monthly Rental Rate: $147,545.69
- Rent Credit Received: $44,169.14 (for June 2025)
- Future Rate Adjustment: 4% increase scheduled for April 15, 2027
Material Changes
The primary material change is the execution of the Second Amendment to the License Agreement with MIL 40G, LLC. Key modifications include:
- Cost Reduction: A significant decrease in the monthly rental rate, reducing the Company's fixed operating costs.
- Term Extension: The lease term was extended from April 14, 2026, to April 14, 2028.
- Retroactive Adjustment: The Licensor provided a partial credit for rent overpaid in June 2025 under the new rate structure.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of risks beyond the standard legal disclaimer that the summary is subject to the complete text of the agreement. The agreement text will be filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2025.
Investor Verification Checklist
- Verify the total annualized savings resulting from the reduced monthly rental rate.
- Review the full text of the Second Amendment (to be filed in the Q2 2025 Form 10-Q) for any hidden covenants or termination clauses.
- Confirm the impact of the $44,169.14 credit on the Company's cash position for the quarter.
- Assess whether the extended lease term aligns with the Company's projected operational needs through 2028.